The present invention relates to compounds of formula (I-VII)
or a pharmaceutically acceptable salt or prodrug thereof, in which A, L, R
6
, R
7
and R
8
are defined herein. The present invention also relates to methods of trating pain using these compounds and pharmaceutical compositions including these compounds.
[EN] NOVEL COMPOUNDS AS MODULATORS OF GPR-119<br/>[FR] NOUVEAUX COMPOSES UTILISES COMME MODULATEURS DE GPR-119
申请人:RHIZEN PHARMACEUTICALS SA
公开号:WO2012170867A1
公开(公告)日:2012-12-13
The present invention relates to novel compounds of formula (A) and (B) as modulators of GPR-119, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of GPR-119 mediated diseases or disorders with them.
Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.
Compounds of formula (1), and pharmaceutically acceptable salts thereof, are capable of blockading voltage-dependent sodium channels and are useful in particular, in treating glaucoma and multiple sclerosis.
[EN] BLOCKADE OF VOLTAGE DEPENDENT SODIUM CHANNELS<br/>[FR] BLOCAGE DE CANAUX SODIQUES DEPENDANT DE LA TENSION
申请人:UNIV LONDON
公开号:WO2001057024A1
公开(公告)日:2001-08-09
Compounds of formula (I), and pharmaceutically acceptable salts thereof, are capable of blockading voltage-dependent sodium channels and are useful in particular, in treating glaucoma and multiple sclerosis.